<DOC>
	<DOC>NCT02518620</DOC>
	<brief_summary>The objective of this study is to evaluate the long-term efficacy and safety of ALX-0061 administered subcutaneously (s.c.) to subjects with active Rheumatoid Arthritis (RA).</brief_summary>
	<brief_title>An Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Must have been eligible for one of the preceding Phase IIb studies with ALX 0061 (study ALX0061C201 or ALX0061C202), have been randomized to placebo or one of the ALX0061 arms (subjects randomized to tocilizumab [TCZ] in study ALX0061C202 are not eligible). Must have reached a response at the end of treatment visit in the preceding Phase IIb ALX0061C201, or ALX0061C202 study. Others as defined in the protocol Received tocilizumab during the previous Study ALX0061C202. Others as defined in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>